ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Continuing its recent biotech investment spree, Russian Corporation of Nanotechnologies has invested a total of $50 million in the nanomedicine-based companies Bind Biosciences and Selecta Biosciences. Including contributions from other new and current investors, the two Boston-area firms have raised a total of $94.5 million in this funding round. Both firms use technologies originating at Harvard Medical School and MIT. As part of the Rusnano deal, Bind and Selecta are setting up subsidiaries in Russia to advance their technologies and to access scientific expertise, clinical-trial resources, manufacturing capabilities, and markets.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X